Format

Send to

Choose Destination
Surg Oncol. 2019 Sep 5;31:33-37. doi: 10.1016/j.suronc.2019.09.002. [Epub ahead of print]

Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for patients at High-Risk of Peritoneal Metastases.

Author information

1
Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
2
Department of Surgery, University of Louisville School of Medicine, Louisville, KY, USA.
3
Department of Pathology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
4
Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address: abbott@surgery.wisc.edu.

Abstract

BACKGROUND:

Selection of patients for hyperthermic intraperitoneal chemotherapy (HIPEC) continues to evolve. We hypothesized that adjuvant HIPEC for patients at high-risk of peritoneal progression is safe and associated with favorable outcomes.

METHODS:

The institutional database of a high-volume center was queried for patients with high-risk disease undergoing HIPEC with a peritoneal carcinomatosis index (PCI) of 0. High-risk patients were defined as those with ruptured primary tumors or locally advanced (T4) disease.

RESULTS:

37 patients underwent adjuvant HIPEC, with a median follow-up of 5.2 years. 54% had low-grade (LG) tumors while 46% had high-grade (HG) tumors. No patients underwent neoadjuvant chemotherapy, while eleven patients (32.4%) received adjuvant chemotherapy. There were no perioperative mortalities, and the overall complication rate was 43%. For the entire cohort, five year recurrence-free survival (RFS) and overall survival (OS) were 77% and 100%, respectively. Five year RFS and OS were 75% and 100% for LG patients and 81% and 100% for HG patients, respectively.

CONCLUSIONS:

Adjuvant HIPEC for patients at high-risk of peritoneal progression, with PCI 0, is safe and associated with favorable long-term survival. Additional prospective investigation is needed to identify patient populations who may benefit most from HIPEC.

KEYWORDS:

Adjuvant perfusion; HIPEC; Peritoneal carcinomatosis; Tumor rupture

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center